Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
IPO Year: 2017
Exchange: NASDAQ
Website: celcuity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | $29.00 | Outperform | Leerink Partners |
| 2/22/2024 | $40.00 | Buy | Stifel |
| 12/8/2023 | $27.00 | Buy | H.C. Wainwright |
| 10/8/2021 | $50.00 | Buy | Canaccord Genuity |
| 9/7/2021 | $48.00 | Buy | Jefferies |
| 7/29/2021 | Outperform | Cowen | |
| 7/27/2021 | $50.00 | Buy | Needham |
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4/A - Celcuity Inc. (0001603454) (Issuer)
4/A - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
10-Q - Celcuity Inc. (0001603454) (Filer)
8-K - Celcuity Inc. (0001603454) (Filer)
D/A - Celcuity Inc. (0001603454) (Filer)
8-K - Celcuity Inc. (0001603454) (Filer)
S-3 - Celcuity Inc. (0001603454) (Filer)
DEFA14A - Celcuity Inc. (0001603454) (Filer)
DEF 14A - Celcuity Inc. (0001603454) (Filer)
PRE 14A - Celcuity Inc. (0001603454) (Filer)
10-Q - Celcuity Inc. (0001603454) (Filer)
8-K - Celcuity Inc. (0001603454) (Filer)
Leerink Partners initiated coverage of Celcuity with a rating of Outperform and set a new price target of $29.00
Stifel initiated coverage of Celcuity with a rating of Buy and set a new price target of $40.00
H.C. Wainwright initiated coverage of Celcuity with a rating of Buy and set a new price target of $27.00
Canaccord Genuity initiated coverage of Celcuity with a rating of Buy and set a new price target of $50.00
Jefferies initiated coverage of Celcuity with a rating of Buy and set a new price target of $48.00
Cowen initiated coverage of Celcuity with a rating of Outperform
Needham initiated coverage of Celcuity with a rating of Buy and set a new price target of $50.00
HC Wainwright resumed coverage of Celcuity with a rating of Buy and set a new price target of $19.00 from $18.00 previously
Craig Hallum reiterated coverage of Celcuity with a rating of Buy and set a new price target of $24.00 from $19.00 previously
H.C. Wainwright reiterated coverage of Celcuity with a rating of Buy and set a new price target of $18.00 from $14.00 previously
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio
Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel
MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as VP of Quality Assurance and Process Development."We are pleased to welcome Michael and David to the Celcuity leadership team. Each brings extensive experience across the biopharmaceutical development spectrum, and each has a fantastic track record," said Brian Sullivan, Celcuity's Chief Executive O
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical drug development and operations team. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development and Jill Krause joined as VP of Clinical Operations."We are very excited to have Igor and Jill join Celcuity and lead our clinical development and clinical operations teams. Each has very relevant experience at both large pharmaceutical and small biopharma companies," said Celcuity's Chairman and Ch
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash equivalents and investments at end of Q3 2024 expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, November 14, 2024, at 4:30 p.m. ET MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments.
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2024 Healthcare Conference at 1:15 p.m. ET on Tuesday, November 19, 2024. A live webcast will be available using this weblink: https://wsw.com/webcast/stifel96/celc/2061562; andA fireside chat at the Jefferies London Healthcare Conference at 11:30 a.m. GMT/6:30 a.m. ET on Thursday, November 21, 2024. A
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webl
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025Expect to reach enrollment target for VIKTORIA-1 PIK3CA WT cohort in Q4 2024 and report topline data for this cohort in late Q4 2024 or Q1 2025Raised $129 million in gross proceeds from equity and debt financings; extending runway of current operational activities through 2026Management to host webcast and conference call today, August 14, 2024, at 4:30 p.m. ET MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-sta
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webl
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the event will be available using this weblink https://wsw.com/webcast/jeff302/celc/1809904. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentat
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners L.P., a U.S.-based healthcare focused investor, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management and Blue Owl Healthcare Opportunities. The offering is expected to close on or about May 31, 2024, subject to satisfaction o
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistantReceived an additional term loan of approximately $62 million in conjunction with an amendment to an existing debt facility agreement MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanc
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer $177.7 million in cash, cash equivalents and short-term investments expected to provide runway into the first half of 2026 Management to host webcast and conference call today, May 15, 2024, at 4:30 p.m. ET MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today annou
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-888-886-7786 and international callers should dial 1-416-764-8658. A live webcast presentation can also be accessed using this weblink: ht
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash equivalents and investments at end of Q3 2024 expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, November 14, 2024, at 4:30 p.m. ET MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webl
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025Expect to reach enrollment target for VIKTORIA-1 PIK3CA WT cohort in Q4 2024 and report topline data for this cohort in late Q4 2024 or Q1 2025Raised $129 million in gross proceeds from equity and debt financings; extending runway of current operational activities through 2026Management to host webcast and conference call today, August 14, 2024, at 4:30 p.m. ET MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-sta
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webl
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer $177.7 million in cash, cash equivalents and short-term investments expected to provide runway into the first half of 2026 Management to host webcast and conference call today, May 15, 2024, at 4:30 p.m. ET MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today annou
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-888-886-7786 and international callers should dial 1-416-764-8658. A live webcast presentation can also be accessed using this weblink: ht
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mTOR inhibitors at the 2023 SABCSRaised $65 million from the sale of equity; expect cash, cash equivalents, investments and available funds under our debt facility, to fund current operational activities into first half of 2026 Management to host webcast and conference call today, March 27, 2024, at 4:30 p.m. ET MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stag
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-888-886-7786 or 1-416-764-8658. A live webcast presentation can also be accessed using this weblink: https://viavid.web
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) for planned Phase 1b/2 clinical trialRaised $50 million in private placement sale of equityManagement to host webcast and conference call today, November 13, 2023, at 8:00 a.m. ET MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial result
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-877-407-0784 or1-201-689-8560. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/start
Leerink Partners analyst Andrew Berens initiates coverage on Celcuity (NASDAQ:CELC) with a Outperform rating and announces Price Target of $29.
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $24 to $23.
Celcuity today entered into an amendment to an existing debt facility agreement and received an additional term loan of approximately $62 million.
Stifel analyst Bradley Canino maintains Celcuity (NASDAQ:CELC) with a Buy and maintains $40 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $27 price target.
Craig-Hallum analyst Alexander Nowak assumes Celcuity (NASDAQ:CELC) with a Buy rating and raises Price Target to $27.
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $24 price target.
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.71) by 16.9 percent.
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $24 price target.